Invesco Dorsey Wright Healthcare Momentum ETF (PTH)
| Assets | $138.62M |
| Expense Ratio | 0.60% |
| PE Ratio | 9.58 |
| Shares Out | 3.25M |
| Dividend (ttm) | $0.03 |
| Dividend Yield | 0.06% |
| Ex-Dividend Date | Jun 24, 2024 |
| Payout Ratio | 0.57% |
| 1-Year Return | +7.60% |
| Volume | 4,006 |
| Open | 42.85 |
| Previous Close | 43.05 |
| Day's Range | 42.59 - 42.93 |
| 52-Week Low | 29.08 |
| 52-Week High | 47.22 |
| Beta | 1.26 |
| Holdings | 53 |
| Inception Date | Oct 12, 2006 |
About PTH
Fund Home PageThe Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an index of U.S. healthcare firms selected and weighted by price momentum. PTH was launched on Oct 12, 2006 and is issued by Invesco.
Top 10 Holdings
37.31% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 5.29% |
| Medpace Holdings, Inc. | MEDP | 4.58% |
| Insmed Incorporated | INSM | 4.36% |
| TransMedics Group, Inc. | TMDX | 4.33% |
| Tenet Healthcare Corporation | THC | 3.84% |
| Hims & Hers Health, Inc. | HIMS | 3.59% |
| Natera, Inc. | NTRA | 3.02% |
| Regeneron Pharmaceuticals, Inc. | REGN | 2.88% |
| ADMA Biologics, Inc. | ADMA | 2.77% |
| Intuitive Surgical, Inc. | ISRG | 2.64% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 24, 2024 | $0.02545 | Jun 28, 2024 |
| Dec 20, 2013 | $0.0114 | Dec 31, 2013 |
| Sep 20, 2013 | $0.0026 | Sep 30, 2013 |
| Jun 21, 2013 | $0.0368 | Jun 28, 2013 |
| Dec 21, 2012 | $0.109 | Dec 31, 2012 |
| Jun 15, 2012 | $0.0084 | Jun 29, 2012 |
News
Best Growth ETFs for Q2 2021
The best growth ETFs for Q2 2021 are OGIG, PTF, and PTH.
Best Healthcare ETFs for Q1 2021
The best healthcare ETFs for Q1 2021 are ARKG, PTH, and KURE.
3 Health Care ETFs Where Components Are Enduring Downgrades
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
3 ETFs To Play Gilead's $21B Immunomedics Takeover
Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion.
Specialty biotech funds jump on promising coronavirus, funding news
Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...
3 ETFs in Focus as Race for Vaccine Intensifies
Several companies sit at the forefront of developing a coronavirus vaccine. Gain exposure to each using the following three ETFs.